[HTML][HTML] Pembrolizumab as second-line therapy for advanced urothelial carcinoma
…, H Gurney, DI Quinn, S Culine… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced urothelial carcinoma that progresses after platinum-based
chemotherapy have a poor prognosis and limited treatment options. Methods In this open-…
chemotherapy have a poor prognosis and limited treatment options. Methods In this open-…
[PDF][PDF] Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced …
…, P Hurteloup, E Winquist, N Morsli, Y Salhi, S Culine… - J Clin …, 2009 - researchgate.net
Purpose Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional
cell carcinoma of urothelial tract (TCCU). We conducted a randomized phase III study of VFL …
cell carcinoma of urothelial tract (TCCU). We conducted a randomized phase III study of VFL …
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group …
…, J Classen, C Clemm, G Cohn-Cedermark, S Culine… - European urology, 2008 - Elsevier
OBJECTIVES: The first consensus report presented by the European Germ Cell Cancer
Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many …
Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many …
Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival …
…, C Théodore, G Deplanque, JM Ferrero, S Culine… - European urology, 2016 - Elsevier
Background The role of chemotherapy in metastatic non castrate prostate cancer (mNCPC)
is debated. Survival benefits of docetaxel (D) added to androgen-deprivation therapy (ADT) …
is debated. Survival benefits of docetaxel (D) added to androgen-deprivation therapy (ADT) …
[PDF][PDF] Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
…, FAB Schutz, Y Salhi, E Winquist, S Culine… - Journal of Clinical …, 2010 - researchgate.net
Purpose The present study sought to identify pretreatment prognostic factors for overall
survival (OS) in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) …
survival (OS) in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) …
[HTML][HTML] Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 …
…, A Necchi, W Gerritsen, H Gurney, DI Quinn, S Culine… - Annals of …, 2019 - Elsevier
Background Novel second-line treatments are needed for patients with advanced urothelial
cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall …
cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall …
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a …
…, AL Martin, M Habibian, A Laplanche, S Culine - The Lancet …, 2015 - thelancet.com
Background Early risk-stratified chemotherapy is a standard treatment for breast, colorectal,
and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and …
and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and …
[PDF][PDF] Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery …
…, JT Hartmann, HJ Schmoll, SB Kaye, S Culine… - Journal of clinical …, 2001 - Citeseer
Purpose: To assess the value of postsurgery chemotherapy in patients with disseminated
nonseminomatous germ-cell tumors (NSGCTs) and viable residual disease after first-line …
nonseminomatous germ-cell tumors (NSGCTs) and viable residual disease after first-line …
Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice
…, C Avancès, Y Allory, A De La Taille, S Culine… - Molecular cancer …, 2010 - AACR
Increased de novo fatty acid (FA) synthesis is one hallmark of tumor cells, including prostate
cancer. We present here our most recent results showing that lipid composition in human …
cancer. We present here our most recent results showing that lipid composition in human …
Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle …
…, F Joly, M Soulié, Y Allory, V Harter, S Culine… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE The optimal perioperative chemotherapy regimen for patients with nonmetastatic
muscle-invasive bladder cancer is not defined. PATIENTS AND METHODS Between …
muscle-invasive bladder cancer is not defined. PATIENTS AND METHODS Between …